title: [Vascular morphological and microdensity changes of corneal neovascularization induced by topical bevacizumab and sunitinib in an animal model].
abstract: OBJECTIVE
  To evaluate the effects of topical bevacizumab and topical sunitinib on vascular microdensity and morphology of corneal neovascularization (NV).
  
  
  METHODS
  A total of 33 rabbits were distributed into 3 groups: group 1 (control; n=11): saline; group 2 (n=11): bevacizumab 5mg/ml; and group 3 (n=11): sunitinib 0.5mg/ml. A corneal NV model was used, based on sutures in the right eye of each rabbit. Each treatment was administered topically 3 times daily for 14 days. Corneas were then processed for the study of vascular microdensity (6 eyes) and vascular morphology analysis (5 eyes) using enzymatic staining histological techniques
  
  
  RESULTS
  The vascular response in group 3 was limited to small-sized tree formations with various vascular axes compared with the extensive, lush and directional corneal NV of group 1 and 2. In the histological sections near the limb, there were no differences in vascular microdensity studies between the three groups. However, the mean sectional area of vessels (MSAV) in group 3 was 41.88% lower than in group 1 and 19.19% lower than in group 2. In distal sections, there were no differences between groups 1 and 2. However, group 3 was characterized by absence of vessels.
  
  
  CONCLUSIONS
  Bevacizumab produced no changes in the morphology of the vessels or the vascular microdensity. Sunitinib reduced the size of the new vessels and induced changes in the vascular tree.
authors.affiliation: Servicio de Oftalmología, Hospital Virgen de los Lirios, Alcoy, Alicante, España; Grupo OftalVist, Alicante, España. Electronic address: jjpsantonja@coma.es.
authors.forename: J J
authors.initials: JJ
authors.lastname: Pérez-Santonja
authors.forename: E
authors.initials: E
authors.lastname: Campos-Mollo
authors.forename: M
authors.initials: M
authors.lastname: Lledó-Riquelme
authors.forename: L
authors.initials: L
authors.lastname: Fernández-Sánchez
authors.forename: N
authors.initials: N
authors.lastname: Cuenca-Navarro
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology / Q000627:therapeutic use*; D001158:Arteries / Q000187:drug effects / Q000648:ultrastructure; D000068258:Bevacizumab; D003315:Cornea / Q000098:blood supply*; D016510:Corneal Neovascularization / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D004357:Drug Synergism; D007211:Indoles / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D010982:Platelet-Derived Growth Factor / Q000037:antagonists & inhibitors; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D011758:Pyrroles / Q000494:pharmacology / Q000627:therapeutic use*; D011817:Rabbits; D000077210:Sunitinib; D013537:Sutures / Q000009:adverse effects; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014680:Veins / Q000187:drug effects / Q000648:ultrastructure
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D007211:Indoles; D010982:Platelet-Derived Growth Factor; D047428:Protein Kinase Inhibitors; D011758:Pyrroles; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000077210:Sunitinib
keywords: Angiogenesis; Angiogénesis; Bevacizumab; Cornea; Corneal neovascularization; Córnea; Neovascularización; Neovascularización corneal; Neovascularization; Sunitinib